A Phase I Trial of Epstein-Barr Virus Gp350 Vaccine for Children With Chronic Kidney Disease Awaiting Transplantation

L. Rees, E.J. Tizard, A.J. Morgan, W.D. Cubitt, S. Finerty, T.A. Oyewole-Eletu, K. Owen, C. Royed, S.J.C. Stevens, R.C. Shroff, M.K. Tanday, A. Wilson, J.M. Middeldorp, P.L. Amlot, N.M. Steven

Research output: Contribution to journalArticleAcademicpeer-review


Background. Vaccination against Epstein-Barr virus (EBV), inducing an antibody response to the envelope glycoprotein gp350, might protect EBV-negative children with chronic kidney disease from lymphoproliferative disease after transplantation. Methods. A phase I trial recruited children with chronic kidney disease to two successive cohorts given three injections of 12.5 mu g (n=6) and 25 mu g (n=10) recombinant gp350/alhydrogel vaccine over 6 to 8 weeks. Results. One in each cohort acquired wild EBV before the week 28 evaluation. Both doses were similarly immunogenic, inducing an IgG response in all 13 evaluable patients. Neutralizing antibodies were detected in four recipients (1/4 in the 12.5 mu g and 3/9 in the 25 mu g cohort). Median time from first vaccination to transplantation was 24 weeks. Immune responses declined rapidly and were unlikely to affect posttransplant events. Discussion. The vaccine was immunogenic but a prolonged vaccine schedule up to time of transplantation or improved adjuvants are required in future trials to reduce posttransplant EBV load and risk of lymphoproliferative disease
Original languageUndefined/Unknown
Pages (from-to)1025-1029
Issue number8
Publication statusPublished - 2009

Cite this